Zobrazeno 1 - 10 of 35 pro vyhledávání: '"MARCO ORSINI FEDERICI"'
1
Akademický článek
The role of patient preferences in adherence to treatment in chronic disease: a narrative review
Autor: Serena Losi, Cesare Celeste Federico Berra, Riccardo Fornengo, Dario Pitocco, Giovanni Biricolti, Marco Orsini Federici
Publikováno v: Drug Target Insights, Vol 15, Iss 1 (2021)
Adherence to prescribed medication is important to the management of all diseases, especially those of chronic nature. Drug effectiveness is substantially compromised by therapy nonadherence. We reviewed the available evidences on the impact of patie
Externí odkaz: https://doaj.org/article/393ee730b4ac48cb847c7a86e303c607
Zobrazit plný text záznamu
4
The role of patient preferences in adherence to treatment in chronic disease: a narrative review
Autor: Giovanni Biricolti, Cesare Celeste Federico Berra, Marco Orsini Federici, Serena Losi, Riccardo Fornengo, Dario Pitocco
Publikováno v: Drug Target Insights, Vol 15, Iss 1 (2021)
Drug Target Insights
Adherence to prescribed medication is important to the management of all diseases, especially those of chronic nature. Drug effectiveness is substantially compromised by therapy nonadherence. We reviewed the available evidences on the impact of patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7afeb3299d35362d91cbfbce0d718f9
https://doi.org/10.33393/dti.2021.2342
Zobrazit plný text záznamu
6
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
Autor: Francesco Giorgino, R. Gentilella, Marco Orsini Federici, Kristina S. Boye, Bruno Guerci, Hélène Sapin, U. Aigner, Luis-Emilio Garcia-Perez, Heike Jung, E. Heitmann, Kirsi Norrbacka, Myriam Rosilio
Publikováno v: Diabetes Therapy
Introduction The TROPHIES observational study enrolled patients with type 2 diabetes mellitus (T2DM) initiating their first injectable treatment with the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) dulaglutide or liraglutide. This manuscrip
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b3086660553c8107e7ebba45cb6e4b
https://doi.org/10.1007/s13300-021-01076-0
Zobrazit plný text záznamu
8
746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis
Autor: FRANCESCO GIORGINO, BRUNO GUERCI, LUIS-EMILIO GARCIA-PEREZ, MARTIN FUECHTENBUSCH, JEREMIE LEBREC, MARCO ORSINI FEDERICI, ANNE DIB, ELKE HEITMANN, MARIA YU, KRISTINA BOYE
Publikováno v: Diabetes. 71
TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in F
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c39fe6c90eb45b6631c1d22d7a979258
https://doi.org/10.2337/db22-746-p
Zobrazit plný text záznamu
9
738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes
Autor: MARTIN FUECHTENBUSCH, BRUNO GUERCI, FRANCESCO GIORGINO, LUIS-EMILIO GARCIA-PEREZ, ELKE HEITMANN, JEREMIE LEBREC, ANNABEL BARRETT, ANNE DIB, MARCO ORSINI FEDERICI, KRISTINA BOYE
Publikováno v: Diabetes. 71
Data on patient-reported outcome (PRO) measures in people living with T2D who initiate injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication in routine clinical practice are limited. Here we present final PRO data from the TROPHIE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f5e8e06eb9893cb260968c41a07c9a2
https://doi.org/10.2337/db22-738-p
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje